EWM
REGN icon

Executive Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Executive Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-16
Closed -$5K – 627
2019
Q2 		$5K Hold
16
– – ﹤0.01% 723
2019
Q1 		$7K Hold
16
– – ﹤0.01% 607
2018
Q4 		$6K Buy
+16
New +$5.86K ﹤0.01% 647

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

Executive Wealth Management's REGN Position: Q3 2019 in Review

Executive Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2019, closing a stake of 16 shares — an estimated $5K sold.

Executive Wealth Management first reported a position in REGN in Q4 2018 and held it in 3 quarters. The position peaked at $7K in Q1 2019. 632 funds tracked by Wall St. Rank hold REGN as of Q3 2019.

  • Executive Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Executive Wealth Management sold 16 Regeneron Pharmaceuticals shares in Q3 2019, an estimated $5K.
  • Executive Wealth Management first reported a position in Regeneron Pharmaceuticals in Q4 2018 and held it in 3 quarters.
  • Executive Wealth Management's Regeneron Pharmaceuticals position peaked at $7K in Q1 2019.
  • 632 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2019.

Based on Executive Wealth Management's 13F filing for Q3 2019, filed 30 Oct 2019.